TY - CHAP
T1 - Gastric electrical stimulation
T2 - Twentieth century development to twenty-first century implementation and personalization of programming
AU - Griffith, James
AU - Daram, Sumanth
AU - Boatright, Ben
AU - Hughes, Joy
AU - Lahr, Christopher J.
AU - Kedar, Archana
AU - Abell, Thomas L.
N1 - Publisher Copyright:
© 2013, Springer Science+Business Media Dordrecht.
PY - 2013
Y1 - 2013
N2 - Gastroparesis is an incompletely understood disorder characterized by vomiting, nausea, abdominal pain, and related symptoms amongst evidence of delayed gastric emptying often refractory to medical therapy. Gastric electrical stimulation (GES), using higher than physiologic frequency and low energy, has been shown to be effective in many patients with refractory symptoms and received Humanitarian Use Device approval in 2000. A meta-analysis suggests GES is effective for symptom control and favorable in gastric emptying, nutritional status, and quality of life analysis. Recent work with endoscopically placed, temporary GES indicates trial stimulation is important in the evaluation of stimulation devices. In addition, approximately 50 % of patients responded to standard settings [4, Neurogastroenterol Motil 18(4):334–338, 2006] while other patients require higher energy settings for optimal response. These recent studies offer the potential for personalization of stimulation parameters in a given patient. For GES to be accepted and adopted on more widespread basis, further evaluation of individual responses to simulation must be determined and then correlated with individual histologic, electrophysiological and biochemical findings to optimally help patients. This chapter will discuss the historical development of current GES therapy.
AB - Gastroparesis is an incompletely understood disorder characterized by vomiting, nausea, abdominal pain, and related symptoms amongst evidence of delayed gastric emptying often refractory to medical therapy. Gastric electrical stimulation (GES), using higher than physiologic frequency and low energy, has been shown to be effective in many patients with refractory symptoms and received Humanitarian Use Device approval in 2000. A meta-analysis suggests GES is effective for symptom control and favorable in gastric emptying, nutritional status, and quality of life analysis. Recent work with endoscopically placed, temporary GES indicates trial stimulation is important in the evaluation of stimulation devices. In addition, approximately 50 % of patients responded to standard settings [4, Neurogastroenterol Motil 18(4):334–338, 2006] while other patients require higher energy settings for optimal response. These recent studies offer the potential for personalization of stimulation parameters in a given patient. For GES to be accepted and adopted on more widespread basis, further evaluation of individual responses to simulation must be determined and then correlated with individual histologic, electrophysiological and biochemical findings to optimally help patients. This chapter will discuss the historical development of current GES therapy.
KW - Europe
KW - Obesity
KW - Placebo
KW - Titration
KW - Washout
UR - http://www.scopus.com/inward/record.url?scp=85043449921&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85043449921&partnerID=8YFLogxK
U2 - 10.1007/978-94-007-6561-0_8
DO - 10.1007/978-94-007-6561-0_8
M3 - Chapter
AN - SCOPUS:85043449921
T3 - Lecture Notes in Computational Vision and Biomechanics
SP - 129
EP - 139
BT - Lecture Notes in Computational Vision and Biomechanics
PB - Springer Netherlands
ER -